1 rich Libsyn https://www.libsyn.com 300 600 In TRIUMPH-1, once-weekly retatrutide produced mean weight loss of up to 25% at 80 weeks—but the story extends beyond the scale. ⚖️ 🦵 Less knee osteoarthritis pain 😴 Fewer obstructive sleep apnea events ❤️ Improved cardiometabolic measures 🩸 89–93% with prediabetes reverted to normoglycemia A triple GIP/GLP-1/glucagon receptor agonist may reshape how we think about obesity: not simply kilograms lost, but disease burden reduced. 💡 ⚠️ Gastrointestinal adverse effects remain important. Dr. RR Baliga's 'Podkast for the Kurious Doc'. Where Curiosity meets Clarity! http://www.MasterMedFacts.com <iframe title="Libsyn Player" style="border: none" src="//html5-player.libsyn.com/embed/episode/id/43154243/height/300/theme/custom/thumbnail/yes/direction/forward/render-playlist/no/custom-color/88AA3C/" height="300" width="600" scrolling="no" allowfullscreen webkitallowfullscreen mozallowfullscreen oallowfullscreen msallowfullscreen></iframe> https://assets.libsyn.com/secure/content/207053058